Vestal Point Capital LP Buys 260,000 Shares of Liquidia Co. (NASDAQ:LQDA)

Vestal Point Capital LP increased its stake in shares of Liquidia Co. (NASDAQ:LQDA - Free Report) by 17.3% in the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 1,760,000 shares of the company's stock after buying an additional 260,000 shares during the period. Vestal Point Capital LP owned 2.08% of Liquidia worth $20,698,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also modified their holdings of LQDA. LM Advisors LLC bought a new stake in shares of Liquidia during the 4th quarter worth about $25,948,000. Invesco Ltd. boosted its holdings in shares of Liquidia by 2,675.0% during the 4th quarter. Invesco Ltd. now owns 700,171 shares of the company's stock worth $8,234,000 after buying an additional 674,940 shares during the period. Janus Henderson Group PLC boosted its holdings in Liquidia by 1,484.5% in the 4th quarter. Janus Henderson Group PLC now owns 535,552 shares of the company's stock valued at $6,293,000 after purchasing an additional 501,752 shares during the period. Mirabella Financial Services LLP bought a new stake in Liquidia in the 4th quarter valued at about $5,880,000. Finally, Eversept Partners LP boosted its holdings in Liquidia by 314.1% in the 4th quarter. Eversept Partners LP now owns 571,305 shares of the company's stock valued at $6,719,000 after purchasing an additional 433,356 shares during the period. Institutional investors own 64.54% of the company's stock.

Analyst Ratings Changes

LQDA has been the subject of a number of recent research reports. Scotiabank reissued an "outperform" rating on shares of Liquidia in a report on Monday, May 5th. Raymond James boosted their price objective on shares of Liquidia from $27.00 to $29.00 and gave the company a "strong-buy" rating in a report on Friday, May 9th. Needham & Company LLC reissued a "buy" rating and issued a $25.00 price objective on shares of Liquidia in a report on Monday, May 12th. Finally, HC Wainwright reissued a "buy" rating and issued a $29.00 price objective on shares of Liquidia in a report on Monday, May 12th. One research analyst has rated the stock with a hold rating, six have given a buy rating and two have given a strong buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of "Buy" and a consensus target price of $27.13.

Insider Buying and Selling

In related news, insider Jason Adair sold 1,856 shares of the company's stock in a transaction that occurred on Monday, April 14th. The shares were sold at an average price of $13.57, for a total transaction of $25,185.92. Following the completion of the transaction, the insider now directly owns 184,304 shares in the company, valued at $2,501,005.28. This represents a 1.00% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Rajeev Saggar sold 2,450 shares of the company's stock in a transaction that occurred on Monday, April 21st. The stock was sold at an average price of $13.67, for a total transaction of $33,491.50. Following the transaction, the insider now owns 263,152 shares of the company's stock, valued at approximately $3,597,287.84. This represents a 0.92% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 33,138 shares of company stock worth $450,233 in the last three months. 26.50% of the stock is owned by corporate insiders.

Liquidia Trading Down 2.2%

Shares of Liquidia stock opened at $18.88 on Monday. The company has a 50 day moving average of $14.56 and a 200-day moving average of $13.41. Liquidia Co. has a 1-year low of $8.26 and a 1-year high of $19.41. The company has a market cap of $1.61 billion, a PE ratio of -11.58 and a beta of 0.24.

Liquidia (NASDAQ:LQDA - Get Free Report) last released its quarterly earnings data on Thursday, May 8th. The company reported ($0.45) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.42) by ($0.03). The company had revenue of $3.12 million for the quarter, compared to analyst estimates of $3.23 million. Liquidia had a negative return on equity of 163.21% and a negative net margin of 765.38%. Research analysts forecast that Liquidia Co. will post -1.51 earnings per share for the current year.

About Liquidia

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).

Want to see what other hedge funds are holding LQDA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Liquidia Co. (NASDAQ:LQDA - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.